 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- | KB408 / Krystal Biotech
Trial completion date: Serpentine-1: A Study of KB408 for the Treatment of Alpha-1 Antitrypsin Deficiency (clinicaltrials.gov) - May 5, 2024
P1, N=12, Recruiting, Sponsor: Krystal Biotech, Inc.
Trial completion date: Jun 2025 --> May 2026
- KB408 / Krystal Biotech
Murine Toxicology Study of Repeat-Dose Inhaled KB408, an HSV-1-Based Vector for the Treatment of Alpha-1 Antitrypsin Deficiency (San Diego Convention Center, Area F (Hall A-B2, Ground Level)) - Feb 20, 2024 - Abstract #ATS2024ATS_4208;
Trial completion date: Jun 2025 --> May 2026 KB408 showed no adverse effects and limited biodistribution when delivered via inhalation to mice, supporting the initiation of a first-in-human Phase 1 single ascending dose study.
- || KB408 / Krystal Biotech
Enrollment open: Serpentine-1: A Study of KB408 for the Treatment of Alpha-1 Antitrypsin Deficiency (clinicaltrials.gov) - Feb 6, 2024
P1, N=12, Recruiting, Sponsor: Krystal Biotech, Inc.
KB408 showed no adverse effects and limited biodistribution when delivered via inhalation to mice, supporting the initiation of a first-in-human Phase 1 single ascending dose study. Not yet recruiting --> Recruiting
- KB408 / Krystal Biotech
Nonclinical pharmacology of KB408, an HSV?1?based vector designed for the treatment of alpha?1 antitrypsin deficiency, in the SERPINA1 knockout mouse model () - Oct 15, 2023 - Abstract #ESGCT2023ESGCT_394;
KB408 was also found to be well tolerated in the airways of both healthy and SERPINA1 knock?out immunocompetent mice. Taken together, these observations support the development of KB408 as a novel gene therapy for the treatment of AATD?related lung disease.
- || KB408 / Krystal Biotech
New P1 trial: Serpentine-1: A Study of KB408 for the Treatment of Alpha-1 Antitrypsin Deficiency (clinicaltrials.gov) - Sep 21, 2023
P1, N=12, Not yet recruiting, Sponsor: Krystal Biotech, Inc.